Darmstadt, Germany, August 8, 2017 — Merck, a leading science and technology company, today announced that it has formed a strategic alliance with Baylor College of Medicine (Texas, U.S.) and its vaccine product development partnership (PDP), Texas Children’s Hospital Center for Vaccine Development (Texas Children’s CVD), to advance vaccine research and development for neglected and emerging infections.
The collaboration focuses on bringing vaccines through development to efficiently deliver them to societies in need. Merck’s experts in process development and formulation are working with Texas Children’s CVD scientists at Baylor to optimize the vaccine manufacturing process to increase vaccine stability and yield. Initially, these activities are targeting schistosomiasis, a deadly parasitic disease that affects millions of people a year in tropical and subtropical regions.
“Our purpose is to solve the toughest problems in life science by collaborating with the global scientific community,” said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. “The alliance with Baylor College of Medicine, one of the premier research institutions in the world, is the ideal partnership to advance vaccine development and manufacturing. Together, we will support the fight against infectious diseases.”
The collaboration includes training and exchange of technical know-how in process development and formulation, filling knowledge gaps that exist from research and development to manufacturing, with a focus on neglected and emerging diseases. Dr. Peter Hotez, founding Dean of the National School of Tropical Medicine at Baylor College of Medicine and co-director of the PDP, recently presented on the topic at an Access to Medicine event earlier this year in Darmstadt, Germany.
”We are excited to partner with Merck in order to advance this important vaccine. Today, schistosomiasis is considered one of the world’s most devastating neglected tropical diseases, affecting hundreds of millions of the world’s poorest people. We are excited about our new collaboration with Merck to advance this lifesaving vaccine,” said Dr. Hotez.
Dr. Maria-Elena Bottazzi, Deputy Director of Texas Children’s Hospital Center for Vaccine Development, said, “The scientific knowledge exchange from this partnership will catalyze and accelerate the product development of much-needed vaccines against the diseases of poverty. It will serve as a framework for capacity building and will establish self-reliance in vaccine development and manufacturing around the globe.”
This collaboration, together with Merck’s recently announced public-private partnership with the Australian Institute of Tropical Health and Medicine (James Cook University, Queensland), the Australian Government’s investment promotion agency, and Baylor College of Medicine, furthers both parties’ commitment to advancing research in neglected diseases globally.
About Baylor College of Medicine
Baylor College of Medicine (www.bcm.edu) in Houston is recognized as a premier academic health sciences center and is known for excellence in education, research and patient care. It is the only private medical school in the greater southwest and is ranked 21st among medical schools for research and 8th for primary care by U.S. News & World Report. Baylor is listed 19th among all U.S. medical schools for National Institutes of Health funding and number one in Texas. Located in the Texas Medical Center, Baylor has affiliations with seven teaching hospitals and jointly owns and operates Baylor St. Luke’s Medical Center, part of CHI St. Luke’s Health. Currently, Baylor trains more than 3,000 medical, graduate, nurse anesthesia, physician assistant and orthotics students, as well as residents and post-doctoral fellows.
In 2011, Baylor launched the National School of Tropical Medicine, which together with Texas Children’s Hospital Center for Vaccine Development is leading an innovative product development partnership model for the research & development of new vaccines to combat the world’s neglected tropical diseases.
All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck generated sales of €16.2 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science and EMD Performance Materials.